• SILODOSIN CHEMBL24778 FDA Approved

    Alternate Names:

    AB0009977
    SCHEMBL136973
    Silodosin
    Rapaflo
    1H-INDOLE-7-CARBOXAMIDE, 2,3-DIHYDRO-1-(3-HYDROXYPROPYL)-5-[(2R)-2-[[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYL]AMINO]PROPYL]-
    160970-64-9
    1-(3-OXIDANYLPROPYL)-5-[(2R)-2-[2-[2-[2,2,2-TRIS(FLUORANYL)ETHOXY]PHENOXY]ETHYLAMINO]PROPYL]-2,3-DIHYDROINDOLE-7-CARBOXAMIDE
    1-(3-HYDROXYPROPYL)-5-[(2R)-2-[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYLAMINO]PROPYL]INDOLINE-7-CARBOXAMIDE
    1-(3-HYDROXY-PROPYL)-5-((R)-2-{2-[2-(2,2,2-TRIFLUORO-ETHOXY)-PHENOXY]-ETHYLAMINO}-PROPYL)-2,3-DIHYDRO-1H-INDOLE-7-CARBOXYLIC ACID AMIDE
    (R)-5-[2-[[2-[2-(2,2,2-TRIFLUORO-ETHOXY)PHENOXY]ETHYL]AMINO]PROPYL]-1-(3-HYDROXYPROPYL)-2,3-DIHYDRO-1H-INDOLE-7-CARBOXAMIDE
    SPIRO[1-AZABICYCLO[2.2.2]OCTANE-8,8'-7-OXA-5-AZABICYCLO[4.3.0]NONA-2,4,10-TRIENE]
    I14-33112
    Q-102517
    I14-8796
    A810210
    W-5225
    D01965
    FT-0687491
    FT-0674584
    AM20090780
    SILODOSIN(RAPAFLO)/KAD 3213,KMD 3213
    DB-064382
    SMR004701206
    KB-60443
    HY-10122
    HE070347
    AK163125
    KAD-3213, KMD-3213
    RL02066
    DB06207
    CS-0284
    CID9794392
    CCG-221202
    BS-1011
    AKOS005145899
    DNC004927
    DNC000835
    DCL000450
    CS0060
    BDBM50160154
    AN-927
    ABP000202
    ZINC3806063
    KSO-0400
    KAD-3213
    EBD33557
    ACN-S002529
    PNCPYILNMDWPEY-QGZVFWFLSA-N
    MOLPORT-006-167-837
    C25H32F3N3O4
    MLS006010022
    GTPL493
    CUZ39LUY82
    AC1NSM20
    SILODOSIN [INN:BAN]
    SILODOSIN (JAN/INN)
    URIEF (TN)
    RAPAFLO (TN)
    (R)-1-(3-HYDROXYPROPYL)-5-[2-[[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYL]AMINO]PROPYL]INDOLINE-7-CARBOXAMIDE
    UROREC
    RAPFLO
    RAPILIF
    SILODYXREG
    RAPAFLOREG
    2,3-DIHYDRO-1-(3-HYDROXYPROPYL)-5-[(2R)-2-[[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYL]AMINO]PROPYL]-1H-INDOLE-7-CARBOXAMIDE
    (R)-1-(3-HYDROXYPROPYL)-5-(2-((2-(2-(2,2,2-TRIFLUOROETHOXY)PHENOXY)ETHYL)AMINO)PROPYL)INDOLINE-7-CARBOXAMIDE
    1-(3-HYDROXYPROPYL)-5-[(2R)-2-[2-[2-(2,2,2-TRIFLUOROETHOXY)PHENOXY]ETHYLAMINO]PROPYL]-2,3-DIHYDROINDOLE-7-CARBOXAMIDE
    UNII-CUZ39LUY82
    KAD 3213
    SILODYX
    URIEF
    160970-54-7
    5312125
    135650458
    493

    Drug Info:

    Year of Approval 2008
    Drug Class antispasmodics, urinary
    FDA Approval approved
    Drug Class small molecule
    Drug Indications for treatment of BPH-related urinary symptoms
    Drug Categories urologicals
    Drug Categories urological agents
    Drug Categories therapeutic uses
    Drug Categories physiological effects of drugs
    Drug Categories pharmacologic actions
    Drug Categories p-glycoprotein/abcb1 substrates
    Drug Categories neurotransmitter agents
    Drug Categories molecular mechanisms of pharmacological action
    Drug Categories heterocyclic compounds, 2-ring
    Drug Categories heterocyclic compounds
    Drug Categories genito urinary system and sex hormones
    Drug Categories drugs used in benign prostatic hypertrophy
    Drug Categories cytochrome p-450 cyp3a4 substrates
    Drug Categories chemical actions and uses
    Drug Categories alpha1 antagonists
    Drug Categories alpha-adrenoreceptor antagonists
    Drug Categories adrenergic antagonists
    Drug Categories adrenergic alpha-antagonists
    Drug Categories adrenergic alpha-1 receptor antagonists
    Drug Categories adrenergic agents
    Drug Groups approved
    Drug Type small molecule
    (2 More Sources)